

China National Accord Medicines Corporation Ltd.

Summary of Semi-Annual Report 2022

I. Important Notice

The summary of semi-annual report is excerpted from the full text of the semi-annual report. For the details, investors should carefully read the full text of the semi-annual report published on Juchao Information website (www.cninfo.com.cn) and Shenzhen Stock Exchange Website etc., appointed by CSRC.

All directors are attended the Board Meeting for report deliberation.

Prompt of modified auditing opinion

Applicable Not applicable

Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reporting period

Applicable Not applicable

The Company plans not to carry out cash dividend and bonus distribution and capitalizing of common reserves

Profit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period

Applicable Not applicable

II. Basic information of the company

1. Company profile

Short form of the stock	Sinopharm Accord, Accord B	Stock code	000028, 200028
Stock exchange for listing	Shenzhen Stock Exchange		
Person/Way to contact	Secretary of the Board	Rep. of security affairs	
Name	Chen Changbing	Wang Zhaoyu	
Office add.	Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province	Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province	
Tel.	+(86)755 25875222		+(86)755 25875222
E-mail	gyyzinvestor@sinopharm.com	gyyz0028@sinopharm.com	

2. Main financial data and index

Whether it has retroactive adjustment or re-statement on previous accounting data

□ Yes √ No

	Current Period	Same period of last year	Increase/decrease in this report y-o-y
Operating revenue (RMB)	36,128,910,049.98	33,163,091,887.39	8.94%
Net profit attributable to shareholders of the listed Company (RMB)	674,215,912.93	741,445,013.25	-9.07%
Net profit attributable to shareholders of the listed Company after deducting non-recurring gains and losses (RMB)	652,857,302.76	720,954,408.22	-9.45%
Net cash flow arising from operating activities (RMB)	1,041,664,059.17	1,229,373,283.57	-15.27%
Basic earnings per share (RMB/Share) (note 1)	1.57	1.73	-9.25%
Diluted earnings per share (RMB/Share)	1.57	1.73	-9.25%
Weighted average ROE	4.44%	5.22%	0.78percentage points down
	End of current period	End of last period	Increase/decrease in this report-end over that of last period-end (+,-)
Total assets (RMB)	45,968,980,824.57	42,783,682,431.81	7.45%
Net assets attributable to shareholder of listed Company (RMB)	15,342,295,205.24	14,924,938,052.50	2.80%

3. Number of shareholders and share-holding

Unit: share

Total common shareholders at period-end		43,689	Total preference shareholders with voting rights recovered at end of reporting period (if applicable)	0		
Top ten shareholders						
Full name of Shareholders	Nature of shareholder	Proportion of shares held	Amount of shares held	Amount of restricted shares held	Information of shares pledged, tagged or frozen	
					State of share	Amount
Sinopharm Group Co., Ltd.	State-owned Corporation	56.06%	239,999,991	5,505,770		
FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND	Foreign Corporation	2.52%	10,802,495			

Hong Kong Securities Clearing Company Ltd	Foreign Corporation	1.73%	7,415,259			
China National Pharmaceutical Foreign Trade Corp.	State-owned Corporation	1.24%	5,323,043			
National Social Security Fund 413 Portfolio	Domestic non state-owned Corporation	1.19%	5,100,032			
BBH BOS S/A FIDELITY FD - CHINA FOCUS FD	Foreign Corporation	0.78%	3,358,761			
Fidelity Investment Management (Hong Kong) Limited - Client's fund	Domestic non state-owned Corporation	0.54%	2,301,737			
CPIC Fund - China Pacific Life Insurance Co., Ltd. - with-profit insurance- CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan	Domestic non state-owned Corporation	0.47%	1,999,227			
ICBC-Guolian Andesheng Small Selected Securities Investment Fund	Domestic non state-owned Corporation	0.38%	1,632,000			
UBS AG LONDON BRANCH	Foreign Corporation	0.30%	1,271,030			

Explanation on associated relationship among the aforesaid shareholders	Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have the same actual controller, which is China National Pharmaceutical Group Corporation. It is unknown that there exists no associated relationship or belongs to the consistent actionist among the other tradable shareholders regulated by the Management Measure of Information Disclosure on Change of Shareholding for Listed Companies.
---	--

4. Changes of controlling shareholders or actual controller

Changes of controlling shareholders in reporting period

Applicable Not applicable

Changes of controlling shareholders had no change in reporting period.

Changes of actual controller in reporting period

Applicable Not applicable

Changes of actual controller had no change in reporting period.

5. Total preferred stock shareholders of the Company and shares held by top ten shareholders with preferred stock held

The Company had no shareholders with preferred stock held in the reporting.

6. Bonds in existence as of the approval date of the semi-annual report

Applicable Not applicable

III. Important events

On December 29, 2021, Sinopharm Holding Guoda Drugstore Co., Ltd. (hereinafter referred to as "Guoda Drugstore"), a controlling subsidiary of the Company, entered in to the Letter of Intent for Cooperation on the acquisition of some social retail pharmacy assets of the Company's controlling shareholders with Sinopharm Holding Hubei Co., Ltd. (hereinafter referred to as "Sinopharm Holding Hubei"). For details, please refer to the Sinopharm Accord: Announcement on Related Transactions of Controlling Shareholders' Fulfillment of Commitments and Solving the Problem of Horizontal Competition in Social Retail Pharmacy Assets" (Announcement No.:2021-42) disclosed on www.cninfo.com.cn dated December 31, 2021 .

On June 27, 2022, the seventh meeting of the ninth board of directors of the company reviewed and approved the Proposal on Sinopharm Holding Guoda Drugstore Co., Ltd. Entrusting 100% Equity of Sinopharm Holding (Hubei) Hankou Pharmacy Co., Ltd. and Changing the Way to Solve the Horizontal Competition of Social Retail Pharmacy Assets. The board of directors agreed that Guoda Drugstore and Sinopharm Holding Hubei sign the Equity Escrow Agreement, changing the original method of solving the horizontal competition of social retail pharmacy assets from acquisition to escrow, that is, from Guoda Drugstore purchasing 51% equity of Sinopharm Holding (Hubei) Hankou Pharmacy Co., Ltd. to escrowing 100% of its equity. On June 27, 2022, the

two parties formally signed the Equity Escrow Agreement. For details, please refer to the Sinopharm Accord: Progress Announcement on the Controlling Shareholder's Fulfillment of Commitments and Solving the Problem of Horizontal Competition in Social Retail Pharmacy Assets" (Announcement No.:2022-28) disclosed on www.cninfo.com.cn dated June 29, 2022.

China National Accord Medicines Corporation Ltd.

Legal representative: Lin Zhaoxiong

August 31, 2022